Charles Schwab’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Charles Schwab’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-255,928	Closed	-$27.5M	–	3723
2023 Q1	$27.5M	Sell	255,928 -370	-0.1%	-$42.6K	0.01%	1227
2022 Q4	$28.2M	Buy	256,298 +41,750	+19%	+$2.71M	0.01%	1186
2022 Q3	$12.7M	Buy	214,548 +97,546	+83%	+$4.46M	﹤0.01%	1684
2022 Q2	$3.3M	Sell	117,002 -3,749	-3%	-$109K	﹤0.01%	2374
2022 Q1	$4.56M	Buy	120,751 +3,121	+3%	+$123K	﹤0.01%	2322
2021 Q4	$4.65M	Buy	117,630 +41,919	+55%	+$1.31M	﹤0.01%	2384
2021 Q3	$1.8M	Buy	75,711 +583	+0.8%	+$13.8K	﹤0.01%	2721
2021 Q2	$1.85M	Buy	+75,128	New	+$1.68M	﹤0.01%	2746

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Charles Schwab's RXDX Position: Q2 2023 in Review

Charles Schwab sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 255,928 shares — an estimated $27.5M sold.

Charles Schwab first reported a position in RXDX in Q2 2021 and held it in 8 quarters. The position peaked at $28.2M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Charles Schwab reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Charles Schwab sold 255,928 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $27.5M.
Charles Schwab first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
Charles Schwab's Prometheus Biosciences, Inc. Common Stock position peaked at $28.2M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Charles Schwab's 13F filing for Q2 2023, filed 10 Aug 2023.